McKesson Corporation (MCK)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
$907.99-1.45%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
Broken: Primary pillar broken — Oncology & Multispecialty segment revenue growth: rev +8.0% vs 20.0% target.
McKesson grows earnings about 13% to 16% yearly. Its Oncology segment revenue rose 31% last year. The company increased share buybacks to $7.7 billion. Profit margins remain stable with steady cash flow.
Growth could slow if acquisitions in Oncology stall. Divestitures may disrupt revenue. Share repurchases might not continue at current levels.
The price is about 21% below our fair value near $1014. Analysts expect 8% revenue growth, while we see stronger EPS growth ahead.
Breaks if: EPS growth falls below 13% YoY next fiscal year
Breaks if: Oncology segment revenue growth falls below 20% YoY next fiscal year
Authorization falls significantly below $7 billion within next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on long-term growth. The current thesis is intact, supported by recent strong financial results and management's commitment to growth targets.
The market currently prices MCK as justified, reflecting a low fragility tier despite some execution weaknesses. It is seen as cheap compared to peers, indicating that investors may have lower expectations for future performance.
Management is on track with its long-term earnings growth targets and expanding its Oncology & Multispecialty segment. However, there is a moderate risk due to past performance misses and a recent cybersecurity incident.
The thesis hinges on management's ability to maintain guidance and deliver consistent results. Additionally, the performance of sector peers and broader economic indicators, such as job reports, will influence MCK's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the outlook. McKesson is expanding its Oncology and Multispecialty segment. This acquisition aligns with their growth strategy. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, MCK's growth potential remains strong, but it must navigate several risks. Not investment advice.